Get Quartz in your inbox

Free daily briefing on global business news.

Eli Lilly's weight loss drug combo shed 23% of body weight, topping its own blockbuster

EloraTZP, which pairs tirzepatide with experimental drug eloralintide, outperformed tirzepatide alone in a 48-week Phase 2 trial in patients with obesity and type 2 diabetes

jetcityimage / Getty Images

Eli Lilly $LLY reported Wednesday that its experimental combination therapy EloraTZP produced greater weight loss than its blockbuster drug tirzepatide alone in a mid-stage clinical trial, with patients on the highest dose losing an average of 23.3% of their body weight over 48 weeks.

Participants on the top dose of EloraTZP — 9 milligrams of eloralintide combined with 15 milligrams of tirzepatide — lost an average of 54.1 pounds, compared with 34.4........

© Quartz